Exprs2 was listed on Nasdaq First North in Stockholm on July 29, 2016. See separate announcement HERE.

Exprs2 delivers the essential technological component in future vaccines and immuno-therapeutics, patents pending.

Based in Hørsholm, Denmark, Exprs2 aims to become the dominant protein production technology used in vaccine production.

Founded in 2010 the company has partnered with leading research institutions and biopharmaceutical companies.

In 2015, Gemstone Capital made unsolicited contact to Exprs2 in order to explore a potential IPO.

After 3 meetings, an agreement was signed and the IPO process was started. Please see a detailed testimonial HERE for further details.

Expres2ion [Exprs2] is currently listed on First North, and has been since August 8th, 2017.

For more information, please go to


expres2ion logo